{"entity":{"id":"nct04325828","kind":"trial","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","aka":[],"tldr":"A phase 2 trial of Apalutamide in salivary gland cancers, run by Janssen Pharmaceutical K.K., active and no longer recruiting.","summary":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma is a phase 2 interventional study registered as NCT04325828 by Janssen Pharmaceutical K.K., with 31 participants enrolled, started 2020-04-07 and due to reach its primary completion in 2021-06-09. Interventions recorded: Apalutamide and GnRH Agonist. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04325828","url":"https://clinicaltrials.gov/study/NCT04325828"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["salivary-gland"],"sections":[],"technologies":[],"targets":[],"drugs":["apalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04325828","phase":"2","setting":"An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma","sponsor":"Janssen Pharmaceutical K.K.","enrolled":31,"outcomes":[]},"route":"/trials/nct04325828/","neighbours":{"cancer":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"}],"drug":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"}]}}